US2019105507A1PendingUtilityA1

System and method for optogenetic therapy

Assignee: CIRCUIT THERAPEUTICS INCPriority: Nov 21, 2012Filed: Dec 11, 2018Published: Apr 11, 2019
Est. expiryNov 21, 2032(~6.3 yrs left)· nominal 20-yr term from priority
A61P 9/12A61M 5/142A61N 5/0622A61M 25/0105A61N 2005/0627A61K 38/164A61N 1/3605A61B 17/3403A61N 2005/063A61M 37/0015A61N 2005/0653A61N 2005/0612A61N 2005/0651A61M 2205/3576A61K 38/177A61M 2037/0061A61N 2005/0643A61K 41/00A61N 5/062A61K 38/168A61N 5/0601A61M 2205/50A61B 17/00234A61N 1/0551A61N 2005/0665A61K 38/16A61N 1/36053A61K 48/0075A61K 48/00A61N 2005/0626A61M 5/20A61M 25/0147A61B 2017/3413A61N 2005/0631A61K 41/0057A61M 2037/0023A61N 2005/067A61N 5/067
74
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Configurations are described for utilizing light-activated proteins within cell membranes and subcellular regions to assist with medical treatment paradigms, such as hypertension treatment via anatomically specific and temporally precise modulation of renal plexus activity. The invention provides for proteins, nucleic acids, vectors and methods for genetically targeted expression of light-sensitive proteins to specific cells or defined cell populations. In particular the invention provides systems, devices, and methods for millisecond-timescale temporal control of certain cell activities using moderate light intensities, such as the generation or inhibition of electrical spikes in nerve cells and other excitable cells.

Claims

exact text as granted — not AI-modified
1 . A system for stimulating a tissue structure comprising light sensitive protein, comprising:
 a. an implantable light conductor configured to be permanently coupled between a first subcutaneous location immediately adjacent the tissue structure and a second location selected such that extracorporeal photons directed toward the second location will be transmitted, at least in part, through the implantable light applicator to the targeted tissue structure; and   b. an extracorporeal light source configured to controllably direct photons into the implantable light conductor at the second location in an amount sufficient to cause a change in the light sensitive protein of the tissue structure based at least in part upon a portion of the directed photons reaching the first subcutaneous location.

Join the waitlist — get patent alerts

Track US2019105507A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.